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Abstract: Feline hyperthyroidism is a clinical syndrome related to an excessive production of thy-
roid hormones, and it is considered as a spontaneous animal model for human thyrotoxicosis.
Many shared features between the feline and the human disease have been identified so far, includ-
ing pathogenesis, clinical signs, and treatment options. Although methimazole is considered the
first-choice drug in both species, several side effects have been described. Furthermore, methimazole
could interfere with the oxidative status, already perturbated by the disease. It has been reported
in humans that dietary management, mainly through antioxidant supplementation, could mitigate
this oxidative burden. The purpose of the review is to describe current therapeutic options in the
course of feline hyperthyroidism and to summarize the state of the art relationship between dietary
antioxidants administration and the reduction of methimazole side-effects in humans to support the
use of this approach also in cats.
Keywords: feline hyperthyroidism; spontaneous animal model; thyroid; thyroid hormones; T3; T4;
TSH; oxidative stress; methimazole; antioxidants
1. Introduction
The term “hyperthyroidism”, as described in humans, is an endocrine disorder where
the thyroid gland produces excessive thyroid hormones. [1]. Similarly, feline hyperthy-
roidism (FHT) must also be considered as a multisystem disorder due to an increased
production of thyroid hormones by the hyperfunctioning thyroid tissue. [2,3]. In addition,
humans and cats share many common features of the disease such as clinical presentation
and physiopathology. In cats, the disease most often results from benign adenomatous
nodules of the thyroid tissue, making it like Plummer’s disease (toxic nodular goiter), while
clinical and therapeutic management are comparable with the Basedow-Graves’ disease [4].
Metabolic oxidation has been correlated, both in hyperthyroid humans and cats, with
signs and symptoms of the disease [5]; the decrease in antioxidant defenses and therefore
the boost in oxidative stress can also be considered a risk factor for several idiosyncratic
drug toxicity syndromes to anti-thyroid drugs, such as methimazole [6,7]. Achievement of
euthyroidism results in normalization of redox markers [8–10], while the severity of clinical
signs and the occurrence of methimazole-adverse reactions could be mitigated by the si-
multaneous administration of dietary supplements (e.g., antioxidants) [11–13]. The aim of
this work is to (1) describe current therapeutic options in course of feline hyperthyroidism,
with particular emphasis on nutritional management and (2) to summarize the state of the
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art relationship between the dietary supplementation of selected antioxidant molecules
(such as curcumin, quercetin, resveratrol and vitamin E) and the reduction of methimazole
side-effects in humans and to identify a possible rationale for this approach also in FHT.
2. Feline Hyperthyroidism
Feline hyperthyroidism is a disease in which there is an increase in the production
and release of tetra-iodothyronine (T4) and triiodothyronine (T3) by the thyroid, with a
suppressed thyroid stimulating hormone (TSH) [3].
2.1. Similarities with Human Disease
The domestic cat is the only animal species in which spontaneous hyperthyroidism
related to senescence occurs frequently enough to allow a systemic investigation of its
pathogenesis. Many common features have been highlighted between human and feline
thyroid disease. In people, hyperthyroidism has been documented starting from 1913
by Plummer; he identified two different clinical presentations: the exophthalmic goiter
(Graves’ disease, GD) and the toxic adenomatous goiter. In GD, increased T4 and T3
production was related to thyroid gland hyperplasia, whereas toxic adenomatous goiter
was characterized by thyroid nodules and variable histological patterns. The latter disease
involves the slow growth of autonomous functioning follicles. Toxic adenomatous goiter
has been also described in hyperthyroid cats starting from 1979 by Peterson et al., and
by two other reports by Holzworth, et al., in 1980 and Jones and Johnstone, in 1981 [14].
However, FHT is also similar to GD in its clinical appearance and therapy [4,15].
Indeed, restlessness, weight loss and tachycardia are shared physical abnormalities phar-
macologically managed by the administration of the same molecules.
2.2. Etiology
In the 1980s, the first studies of FHT associated such a disease with a primary thy-
roid gland abnormality rather than with the effect of circulating TSH, or thyrotropin-
releasing hormone (TRH). Indeed, when the thyroid tissue of hyperthyroid cats was
experimentally transplanted subcutaneously into nude mice under TSH suppression, the
thyroid cells maintained the cuboid shape, the high growth potential and functional
autonomy [4,14]. In addition, Peterson et al., have described that a normal feline thy-
roid gland has subpopulations of follicular cells with high growth potential and TSH
receptors with detectable basal constitutive activity [14]. Consequently, it is believed that
cats destined to develop hyperthyroidism have subgroups of thyroid cells able to self-
replicate and, if in adequate number, also to autonomously synthesize thyroid hormones.
Scott-Moncrieff suggested that long-term stimulation of high growth potential cells make
them autonomous from TSH feedback due to follicular cell mutations. Indeed, mutations
with gain-of-function of the TSH receptor or of the alpha subunit of stimulating G proteins
have been described in humans [4,14]. Eleven TSH receptor mutations were detected in 134
hyperplastic nodules of 50 hyperthyroid cats; five of them were also identified in thyroid
tissue samples collected from hyperthyroid humans. Interestingly, out of the 41 cats with
more than one nodule, 14 had nodules with different mutations [14]. A study conducted
on thyroid adenomas of hyperthyroid cats identified a reduced amount of an inhibitory G
protein as well [4,14]. A further study by Ward et al., suggested that decreased expression
of certain inhibitory G proteins subtypes contributes to the molecular pathogenesis of FHT,
rather than changes in TSH-stimulated G protein activity. Merryman et al., reported an
overexpression of the oncogene product c-Ras in thyroidal nodular hyperplasia/adenoma
tissues from 18 hyperthyroid cats [14]. Taken together, such evidence suggests that the mul-
tiple mutations in thyroid follicular cells may ultimately lead to thyroidal cells autonomy.
Nonetheless, the etiopathogenetic mechanism underlying these mutations remains unclear,
as is the reason why feline clinical overt hyperthyroidism has become much more com-
mon in the last 40 years, enough to make it the most frequent endocrine pathology in the
geriatric age [14–16].
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2.3. Pathogenesis
Primary thyroid disorders are almost always considered as the main cause of feline
thyrotoxicosis. More specifically, hyperthyroid cats are more frequently diagnosed with
follicular cell adenoma and multinodular adenomatous hyperplasia. Both are considered
benign lesions and can occur simultaneously in the same subject. From the histological
point of view, the follicular cells are uniform and cuboidal to columnar in shape with occa-
sional papillary formations, circumscribing secreting follicles [4,14]. Thyroid adenomas are
clearly identifiable by a thin fibrous capsule, sometimes invading the normo-functional
tissue. In adenomatous thyroid hyperplasia, hyperplastic cells are organized in nodules
and can vary in size, from 1 mm to more than 3 cm. Hyperplasia and adenomas are present
in about two thirds of hyperthyroid cats [3]. Malignant neoplasm can affect one or both
thyroid lobes and occurs in 1–3% of cats with FHT. Macroscopically, tumors can be encapsu-
lated, mobile and clinically scarcely distinguishable from benign neoformations. Moreover,
masses can be locally invasive, attached to the surrounding tissues and metastasizing to
the tributary lymph nodes [17]. Feline thyroid cancers are generally well-differentiated
adenocarcinomas composed of a uniform pattern of small follicles containing varying
colloid amounts. Mixed compact and follicular morphological patterns are the most com-
mon, although primitive follicular and papillary patterns have also been described [15].
TSH secreting pituitary adenoma is a rare cause of hyperthyroidism in humans [18], but
not yet documented in cats. Hyperthyroidism following iatrogenic ingestion of thyroid
hormone, already diagnosed in dog fed raw diets, has not been described in cats yet [19].
2.4. Clinical Features
2.4.1. Signalment
The mean age of onset of FHT is 13 years; however, a small number of cases are
described under 4 years of age [14,20]. Several studies describe a greater genetic predispo-
sition in breeds, such as the Siamese and the Himalayan, while a difference in incidence
related to sex has not been demonstrated yet.
2.4.2. Clinical Presentation and Laboratory Abnormalities
The disease is sneaky and progressive, and the severity of symptoms, along with the
stage of the disease at the time of diagnosis depends on the amount of produced hormones.
The most frequent clinical presentation of FHT is a middle-aged or senior, thin (98%),
hungry (81%), restless (76%), tachycardic (66%) and polyuric (60%) cat. Furthermore, the
patient has an anxious and sometimes aggressive behavior, with a reduced tolerance to
any source of external stress [21,22]. In an older cat, weight loss, often coupled with an
increased appetite, may arouse a reasonable suspect of hyperthyroidism. However, in
a small number of cases, clinical signs may differ and can be difficult to hook to FHT.
More specifically, “apathetic hyperthyroidism”, can represent the final evolution of the
disease, capable of leading to heart failure. In severely affected patients, stress and restraint
may also cause a sudden elevation of plasma T4 levels, and they can be considered possible
precipitating factors for the so called “thyroid storm”, a term used for a rare clinical entity
in humans. The multisystemic effects of thyroid hormone excess could also trigger a series
of biochemical modifications and abnormalities. Some abnormalities, such as elevated
plasma concentrations of liver enzymes and increased ratio of urinary corticoids to cre-
atinine, can be managed with antithyroid drug therapy. Hemodynamic changes in FHT
predispose to marked increases in glomerular filtration rate, glomerular hypertension,
and hyperfiltration, often leading to mild proteinuria. Systemic arterial hypertension also
occurs in 10 to 23% of hyperthyroid cats at the time of diagnosis, moreover 1 out of 4
patients initially classified as normotensive may became hypertensive during treatment.
Etiopathogenesis of secondary hypertension in a course of FHT, however, is still debated.
Publications in other species suggest that elevated thyroid hormones may increase cardiac
sensitivity to circulating catecholamines and may also have a direct effect on heart cells [23].
One other major concern is the increase in plasma creatinine concentration following
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hyperthyroidism treatment. The endocrine disease may indeed mask the diagnosis of
underlying chronic kidney disease (CKD), as the glomerular filtration rate (GFR) increases,
and may be associated with loss of muscle mass; these two events may decrease serum
creatinine concentration. Additionally, many hyperthyroid cats with concomitant CKD
exhibit azotemia when GFR and body composition revert to euthyroid states. Currently,
no clinical study can exactly predict which hyperthyroid cats have also a concurrently
masked CKD. Identification of these cats could allow an earliest intervention, influence
the therapeutic choice for the treatment of hyperthyroidism and potentially predict the
onset of a post-treatment iatrogenic hypothyroid state. In hyperthyroid cats, symmetric
dimethylarginine (SDMA) [24], together with urinary isoprostanes (renal oxidative stress
markers) [25] could be used as early-stage kidney damage biomarkers. In a study from Pe-
terson et al. (2018) [24], pretreatment SDMA concentration (>14 µg/dL) was high only in 14
of 42 hyperthyroid feline patients that developed azotemic CKD after treatment. SDMA test
specificity as a predictor of masked azotemia was of 97.7% with a low sensitivity (33.3%).
Although the SDMA concentration was insensitive, it had higher sensitivity than serum
creatinine, even when the cutoff value for this parameter was set well below the upper
limit of the reference interval. Lowering the upper cutoff for serum SDMA concentration
from >14 µg/dL to >12 µg/dL resulted in a two-fold increase in test sensitivity, with only
a slight decrease in specificity. [24].
2.4.3. Diagnosis
When clinical history and biochemical abnormalities are suggestive of FHT diagno-
sis, a thorough palpation of the neck region is recommended. In fact, when the thyroid
glands are enlarged, they descend along the trachea, sometimes reaching the thoracic inlet.
Palpation is a specific examination to detect abnormalities in the shape of one or both
lobes, and up to 90% of the changes can be detected in cats with hyperthyroidism [22].
Rarely, thyroid enlargement results from the presence of ectopic (sometimes intratho-
racic) thyroid tissue. The final diagnosis should be based on direct measurement of
thyroid function: the initial screening test is usually the basal serum concentration of T4.
Reference values for total T4 are between 1 and 4.5 µg/dL in healthy cats. In a study on
917 untreated hyperthyroid feline patients, 221 ill cats suffering from non-thyroid disease
and 172 clinically and biochemically healthy cats, 91% of the hyperthyroid subjects had
elevated serum T4, while none of the cats unaffected by thyroid disease had a total T4
above normal limits. [26]. Today, the inclusion of T4 in many profiles for geriatric cat
facilitates the diagnosis before the disease becomes clinically evident. Such screening
approach is appropriate for the diagnosis of FHT due to its high specificity; however,
it should be remembered that the serum concentration of T4 can also be influenced by
non-thyroid diseases and alterations in metabolism that interfere with hormones binding
to plasma carrier proteins, transport into cells, etc. In fact, according to Scott-Moncrieff,
the serum concentration of fT4, measured by equilibrium dialysis, is a more effective
parameter than the evaluation of the total concentration of T4 in elderly hyperthyroid cats
with concomitant geriatric diseases, such as CKD [14]. However, Rijnberk et al. stated
that “in most cases, measurement of fT4 concentration by direct equilibrium dialysis adds
little or no useful diagnostic information”. “Non-thyroid diseases can be associated with
false positive results and therefore feline hyperthyroidism should not be diagnosed only
when a high concentration of fT4 is found” [22]. To date, the debate on the usefulness of
determining fT4 in feline thyroid dysfunction is still widely open. Cats showing elevated
fT4 and concentration of total T4 within normal limits should undergo other tests (e.g.,
scintigraphy) to confirm hyperthyroidism. Measurement of serum T3 concentration is
scarcely used to diagnose FHT, while serum TSH concentration may have a clinical utility
in selected cases. As effectively described by Peterson et al., serum TSH concentrations
are abated in 98% of hyperthyroid cats, but concentrations are measurable in a few cats
with mild to moderate hyperthyroidism [27]. For this reason, the measurement of serum
TSH should be considered a very sensitive but not specific test for the diagnosis of FHT.
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Although the radioactive iodine uptake test with 131I or 123I is not always available, it
could provide an effective contribution to the diagnosis [22].
3. Treatment Options of Feline Hyperthyroidism
Guidelines for FHT treatment have been recently summarized by Carney et al. (2016),
according to currently available evidence-based knowledge [16]. The present review is
written in line with this publication.
Principal treatment options for FHT, according to [16] are: radioiodine ablation of the
thyroid (radioactive iodine therapy); surgical thyroidectomy; inhibition of secretion by
antithyroid drugs; and administration of iodine-limited diets. The first two therapeutic
alternatives are beyond the scope of the present review, thus only a brief summary of their
pro and cons will be proposed. A thorough assessment of the pharmacological and dietary
approaches will be presented.
3.1. Radioiodine Ablation of the Thyroid (Radio-Iodine Therapy) and Surgical Thyroidectomy
Radioiodine therapy has been recommended as the elective treatment [16,28]; however,
it must be considered that, at present, this therapy is offered only by a limited number of
facilities in some countries; furthermore, the confinement period up to 4 weeks after the
injection of the radioactive compound is considered a limiting factor by the owner.
Surgical thyroidectomy, on the other hand, holds the risk of a general anesthesia in
a geriatric and often unstable patient. Post-surgical complications, such as hypoparathy-
roidism or persistent hyperthyroid status due to ectopic thyroid tissue excreting thyroid
hormones, contribute to reduce the number of patients that annually undergo this kind of
procedure [16,28].
3.2. Antithyroid Drugs
Antithyroid drugs have two main purposes: short-term treatment, generally indi-
cated to stabilize the patient before surgery, and long-term treatment, indicated to mitigate
thyrotoxicosis. Furthermore, a trial with antithyroid drugs before radioiodine therapy or bi-
lateral thyroidectomy can predict the risk of renal damage after definitive therapy [14,16,28].
Two molecules are available as veterinary drugs for the treatment of FHT: methimazole
(MMI) and carbimazole (CMZ). In humans, MMI blocks thyroid peroxidase, thus prevent-
ing the synthesis of thyroid hormones. It is hypothesized that MMI accumulates, in the
same way, in the thyroid glands of cats. Attack therapy of MMI should be an oral dose
of 2.5–5.0 mg per cat twice daily. Twice-daily dosing is associated with less severe side
effects than a higher once-daily dose [28]. However, once the cat is stabilized, administer-
ing the total daily dose every 24 h could increase owner compliance while maintaining
euthyroidism. Most hyperthyroid cats have T4 levels within the reference range within
2–3 weeks from the starting of the treatment with antithyroid drugs [16,28]. Thus, the
monitoring of T4 is recommended after that interval [28]. If the cat is still hyperthyroid,
MMI dose adjustment can be accomplished with 1.25–2.5 mg/day increments until eu-
thyroidism is achieved [28]. When maintenance doses >20 mg/day are needed, owner
compliance should be questioned. If T4 falls below the reference range, MMI dosage
should be reduced in steps of 1.25–2.5 mg/day and T4 and renal parameters should be
re-checked after 1–2 weeks [28]. Unfortunately, oral anti-thyroid drugs are not free from
side-effects. More to the point, administering a pill to a cat, once or twice daily for a
life-long period, can be tricky and waste money [11]. Transdermal application of a pluronic-
lecithin organogel (PLO) containing MMI has been suggested as an alternative treatment
regimen; Hill et al. [29] recently demonstrated that a novel lipophilic formulation was as
effective and safe as twice daily oral CMZ in the treatment of cats with hyperthyroidism.
There are several advantages of the transdermal therapy over the oral therapy. The first
one is represented by the possibility of avoiding the gastric route, reducing the potential
for both degradation of the drug and gastric irritation. Side effects different from gastro-
intestinal signs seem to be less severe and, according to the long-term follow-up study
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from Boretti et al., they do not occur during the first 3 months of treatment, as usually
expected, but after a prolonged use of the gel. The second benefit is the opportunity of a
more accurate dose adjustment [30]. The gel, in fact, is usually dispensed in 1ml (=100 IU)
syringes without needle, with a minimum interval of 0.01 mL or 0.02 mL (=1IU/2IU) on the
graduated scale. The MMI concentration varies from 2.5 mg/0.1 mL to 5 mg/0.1 mL; thus,
the dose can be corrected by 0.125 mg/0.5 mg, which are hardly conceivable with tablets.
Moreover, according to the manufacturer, tablets should not be divided. A further advan-
tage is the non-invasiveness of the procedure and the improved owner compliance with
the drug administration. Referring to possible disadvantages, the first is the absence of a
PLO-based MMI available as a pharmacologically registered product; secondly, studies
have shown a variable bioavailability of MMI in the form of PLO-gel, given as a single trans-
dermal dose in healthy cats, despite a good clinical short-term response in sick cats have
already been documented. Regional variations in percutaneous absorption, licking of the
gel during grooming activity and evidence of trans-pinnal movement of MMI in a lipophilic
vehicle applied to the inner ear in an in vitro model, may also have efficacy and safety im-
plications for both cats and their owners. In a clinical trial performed by the author A.C. on
21 hyperthyroid cats evaluating efficacy, safety and owner compliance during transdermal
MMI treatment, it emerged that it is an effective and safe administration option, at least for
the short-term period, with an excellent owner satisfaction [29,30]. As for the documented
side effects of MMI [31–35], the most common ones concern the gastrointestinal tract, due
to the possible irritating effect of oral MMI on the gastric mucosa, and the facial excoriation,
likely associated with vasculitis. Instead, the most serious but rare disorders are liver
disease and marked blood dyscrasias (severe leukopenia, anemia and/or thrombocytope-
nia). Moreover, other possible but uncommon complaints are lethargy and neuromuscular
weakness, along with positive antibody titers to the acetylcholine receptor, due to acquired
myasthenia gravis. Please see Table 1 for a more exhaustive list of suspected adverse
drug reaction to oral and transdermal MMI. It has not yet been possible to demonstrate
any relationship between MMI dosing regimen (once versus twice daily) and side effects.
It should be noted that most side effects begin within the first 4–6 weeks of therapy and
become less common after 2–3 months of starting treatment [28].
Table 1. Suspected adverse drug reactions to oral and transdermal methimazole (modified from [28]).
Side-Effects Dose Range(Total mg/day) Administration Frequency (%)
Time to Onset
(Days) Recommendation Monitoring/Comments






14 / Liver enzymes function










14 to 28 Discontinue treatment











Within the first 4
weeks
/ cell blood counttwo weeks later
Myasthenia gravis Unknown Oral 4 casesreported 60 to 120
Discontinue treatment,
administer steroids
Anaemia 2.5 to 5 Oral 1 case report After 3 years oftreatment
Discontinue treatment if
anaemia is severe, no re-
challenge
cell blood count 2 weeks
later
Gastro-intestinal


















10 Oral 1 case report Within 2 weeks Discontinue treatment
Antinuclear
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Table 1. Cont.





















3.3. Administration of Iodine-Limited Diets
The administration of iodine-reduced diets is generally considered a valid alternative
for the long-term management of subjects who cannot face a resolutive therapy. In fact, the
reduction of iodine taken with the diet lowers the production of thyroid hormones, even
if it does not always obtain an effective attenuation of clinical signs [36–38]. The utility
of diets at different iodine concentrations from 0.15 mg/kg to 1.9 mg/kg on a dry mat-
ter basis (DMB) were investigated in two reports enrolling 33 hyperthyroid cats [39,40].
All cats were consuming commercial diets containing 1.9 mg/kg of iodine at the time of
the diagnosis of hyperthyroidism. Subjects who ate a diet with a reduced iodine content of
0.17 mg/kg showed normal T4 values within 8 weeks, while cats who ate a diet containing
iodine 0.28 mg/kg became euthyroid by 12 weeks. Conversely, the number of cats that
became euthyroid was lower when they ate diets containing higher iodine concentrations
(0.39 mg/kg [7 out of 9 cats] or 0.47 mg/kg [4 out of 5 cats]). More extensive thyroid pro-
files were also performed in 14 of 33 cats; concentrations of fT4, total T3, free T3 and TSH
were within normal limits during treatment with iodine-restricted feed. If cats receiving
a low-iodine diet do not become euthyroid within 4–8 weeks, it is advised to check for
other sources of iodine-rich food accidentally given, including tap water, medications, or
supplements [15,16]. Dietary therapy of feline FHT doesn’t have a human counterpart
as low iodine diets are used only for a short time in human medicine and for special
diagnostic purposes (e.g., prior to imaging for extra-thyroid metastases). In fact, iodine
is also known to have antioxidant and anti-inflammatory properties, as well as a role in
the prevention of breast cancer and fibrocystic breast disease [41]. One concern is that cats
long-term managed with low-iodine diets may clinically develop goiter due to hyperplas-
tic follicular cells and initiate the transformation from adenomatous nodules to thyroid
cancer. In a report of eight cats with thyroid cancer, two cases had both adenomatous and
carcinomatous cells contained in the same gland, suggesting that the carcinoma derived
from a previous benign neoplasm [42]. Other concerns are related to the poor palatability
of the diet in exigent pets and the possible nutritional inadequacy of such a long-lasting
regimen for geriatric patients that have specific nutritional requirements [15,37,38].
Advantages and disadvantages of the four described treatment options are summa-
rized in Table 2.
Table 2. Advantages and disadvantages of FHT treatment (modified from [14]).
Treatment Advantages Disadvantages
Radioactive Iodine
- Kills abnormal cells
- Cure rate ≥95%
- Rare side effects
- Risk of permanent
hypothyroidism
- Elective treatment in
humans
- Requires special license
and facility
- Hospitalization
- Cat confined for
minimum 2 weeks after
discharge
- Irreversible














- Tumor may become
malignant
Surgical thyroidectomy
- Efficacy ≥90% if both
glands are removed








- Efficacy ≥82% while on
diet.
- Recommended for cats
with CKD
- No other feed permitted
- Relapse rate 100% when
diet is discontinued
4. Mechanisms of MMI-Induced Organ Injury
Possible manifestations of drug-induced damage must be taken into account when
setting up a specific pharmacological therapy. In particular, hepatotoxicity, nephrotoxicity,
vasculitis and blood dyscrasia represent possible clinical complications of antithyroid drugs
used in the treatment of human and feline thyrotoxicosis [28,30,31,33]. As already men-
tioned above, MMI is the most used drug against hyperthyroidism. MMI-organ damage has
been reported, with liver representing the main target. The etiopathogenetic mechanism
of hepatic damage has not been precisely described yet; however, it is thought that mito-
chondrial toxicity caused by an oxidative stress state can trigger cell death and apoptotic
phenomena in hepatocytes. The main enzymatic superfamilies that metabolize MMI are
the haemoproteins (cytochrome P450, CYP 450) and the oxidoreductases, specifically flavin
monooxygenase (FMO). The proposed pathways of bioactivation of MMI in the liver have
already been explained in previous studies [33–35] and is here summarized in Figure 1.
Recently, Niknahad et al. studied the effect of MMI on hepatocyte mitochondria in
two different models (in vitro and in vivo). The results of this study are controversial.
In vivo, MMI caused mitochondrial damage in mice. Instead, in vitro MMI not only did
not cause any mitochondrial damage, but also protect this organelle when isolated liver
mitochondria were treated with different drug concentrations [32]. However, it should be
considered that the observed differences may be associated with the drug bioactivation and
the formation of reactive metabolites in vivo vs in vitro; in fact, biotransformation enzymes
are absent in isolated mitochondria. In previous experiments, Heidari et al. found that
some enzyme inhibitors effectively mitigated MMI-induced cytotoxicity in isolated hepato-
cytes. On the other hand, enzyme induction markedly increased MMI hepatotoxicity [33].
Thus, it becomes clear the importance of reactive metabolites, which must be considered
as pro-oxidizing agents, in MMI-induced mitochondrial and subsequent hepatic dysfunc-
tion. Another investigation has indicated the radical elimination properties of MMI [32].
This study focused on the effect of MMI on IFN-alpha action in FRTL-5 rat thyroid cells.
The results showed that IFN-alpha produced a significant amount of H2O2 in thyroid
cells, inducing the tyrosine phosphorylation of STAT1 and STAT3. Furthermore, Kim et al.
showed that MMI was able to clear H2O2 by one electron reduction, thus preventing re-
versible physiological inactivation of phosphatases in response to IFN-alpha signaling [34].
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The net effect was therefore that MMI inhibited full activation of the JAK/STAT signaling
pathway in FRTL-5 thyroid cells.
Figure 1. Proposed methimazole (MMI) metabolites, and their role in hepatic injury. Reactive intermediates formed
during MMI metabolism may bound to macromolecule targets (e.g, proteins), and cause toxicity or might be detoxified by
nucleophilic molecules such as glutathione [33,34]. FMO: Flavine-containing monooxygenase, CYP 450: cytochrome P450,
GSH: reduced glutathione. Circled numbers: 1: methimazole; 2: epoxide metabolite; 3: dihydrodiol molecule; 4: glyoxal; 5:
N-methyl thiourea; 6: sulfenic acid; 7: sulfinic acid; 8 and 9: other sulfenic and sulfinic acid species.
Taken together, these data suggest a paradoxical effect of MMI in different in vitro and
in vivo models and further studies are needed to elucidate the mechanism of MMI-induced
damage. Additionally, some studies have also suggested a variety of other factors that
could affect drug-induced damage and may not be directly linked to drug metabolism.
Among these, immunological reactions are the best known. An intriguing theory for
immune-mediated drug-induced organ damage is the “haptenic hypothesis” [35]. Consis-
tently with this theory, the reactive metabolites of the drug undergo a covalent bond with
different proteins. The drug-protein complex is then identified by the immune system that,
when activated, could lead to toxicity.
5. Oxidative Stress and Thyroid Hormones
5.1. Free Radical Generation and Antioxidant Defenses
Redox imbalance can be described as a disturbance of the balance between the pro-
duction of free radicals (oxidative stress, OS) and antioxidant defenses, see Figure 2.
Free oxygen radicals (ROS) are the most important in generating oxidative stress, and they
include superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical.
The first three compounds are formed by the oxidation of energy substrates through the
mitochondrial respiratory chain. Among ROS, the hydroxyl radical and the superoxide
anion possess a high reactivity due to the presence of a single unpaired electron in the
external orbital [43]. Double oxidases (DUOX) represent enzymatic steps for the generation
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of hydrogen peroxide and are also essential for the synthesis of the hormone catalyzed
by thyroid peroxidase (TPO), [41]. Furthermore, NADPH oxidase 4 (NOX4) is a novel
intracellular ROS generation system recently identified in the human thyroid [43–46].
Numerous endogenous defense processes against free radicals have been described in vari-
ous cellular localizations (i.e., plasma membrane, mitochondria, peroxisomes and cytosol).
Enzymes that stop or counter the production of free radicals are glutathione peroxidase
(GPx), catalase (CAT), superoxide dismutase (SOD) and transition metal binding proteins,
such as ceruloplasmin, ferritin and transferrin. SOD accelerates the process of dismutation
of the superoxide anion in hydrogen peroxide and molecular oxygen. CAT detoxifies hy-
drogen peroxide by transforming it into molecular oxygen and water. GPx also participates
in the detoxification of hydrogen peroxide when hydrogen peroxide levels are very high.
Furthermore, GPx detoxifies the lipid peroxides by transforming them into the correspond-
ing alcohols. Instead, the “scavenger” molecules, such as vitamin E, albumin, ascorbic acid,
bilirubin, urates and thiols, stop the lipid peroxidation chain by neutralizing the interme-
diate radicals. The high diffusion speed of scavengers, together with their regenerative
capacity, allows them to transform free radicals into more stable molecules [44].
Figure 2. Mechanisms responsible for oxidative stress and cell damage [43–45].
5.2. Hyperthyroidism and Redox Imbalance
Hyperthyroidism is correlated with increased oxygen and intracellular ATP consump-
tion, elevated ROS production and consequent dysfunction in the mitochondrial respiratory
chain. Moreover, some studies underline the role of oxidative disturbances in the initia-
tion of Graves’ disease (GD), Plummer’s disease and hyperthyroidism-induced damage,
such as thyrotoxic myopathy, cardiomyopathy, and Graves’ orbitopathy (GO), [7,46–49].
However, some contradictions still emerge from a literature review related to studies con-
ducted in animals [4,5,11]. Given the above, a summary of results deriving from clinical
and experimental trials on hyperthyroid subjects, focused on evaluating their redox un-
balance, will be presented in the following sections. Given that the more robust scientific
literature has been published with regards to human patients, the first subchapter will be
dedicated to human studies, then feline trials will be presented.
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5.2.1. Human Studies
In humans, most trials assessing the effect of thyroid diseases have been performed
in patients diagnosed with GD, either under hyperthyroid condition or after restoration
of euthyroid state. Untreated thyroidal hyperfunction status is associated with an in-
crease of numerous intracellular and circulating parameters of OS [i.e., lipid peroxides,
hydrogen peroxide, thiobarbituric acid-reacting substances (TBARS), determinable reactive
oxygen metabolites (d-ROMs) and malondialdehyde (MDA)], as compared with basal
concentrations detected under euthyroid state. In patients with overt hyperthyroidism,
levels of circulating thyroid hormones correlate with concentrations of lipid peroxida-
tion metabolites, but significantly higher ROS have also been observed in patients with
a subclinical hyperfunction of the thyroid gland. A novel automated technique for the
evaluation of the OS has been recently applied in hyperthyroid patients, confirming the
existence of a redox burden [7]. Treatment with antithyroid drugs resulted in a declined
concentration of OS markers, which may be related to the restoration of euthyroidism,
as well as to the antioxidant properties of these molecules. Contradictory conclusions
have been stated regarding the activity of the antioxidant defense system in human hyper-
thyroid cases [8,47,48,50]. Most trials have demonstrated an upregulation of antioxidant
defense enzymes, as a homeostatic reaction to counteract the hyperthyroidism-induced
ROS production. Komosinska-Vassev et al. [51] investigated selected markers of antioxi-
dant status in 30 human patients with GD; they found an increase in the activity of some
intracellular antioxidant enzymes (i.e., GPx, SOD and CAT), but not in serum GPx and
total antioxidant status, as compared with age-matched controls. The authors postulate
that the conflicting results between serum and erythrocyte antioxidant activities likely
result in a quicker exhaustion of the antioxidant barrier. Bednarek et al. [9] measured the
plasma antioxidant barrier in 47 GD cases of short duration (1–2 months), with and without
GO, and found that CAT and SOD were increased when compared with healthy controls.
Conversely, other studies have shown no evidence of increased antioxidant defenses in
patients with untreated long-lasting hyperthyroid state [52]. The contradictory data on
antioxidant barrier in patients with GD may be due, in addition to differences in assessment
methods, to the duration of the hyperthyroid status at the time of evaluation. Indeed, in
humans with short-lasting thyroid hyperfunction, we might expect an increment in the an-
tioxidant defense mechanisms to balance the increased OS. On the other hand, in cases with
a more prolonged duration of the hyperthyroid condition, the constant challenge of the
antioxidant barrier system may account for the decreased serum and cellular antioxidant
enzymes. Despite the above discrepancies, the administration of anti-thyroid drugs, able
to restore the normal thyroid function, is usually also associated with the normalization
of endogenous antioxidant defenses. A scavenging effect of MMI may also contribute to
these adjustments [52] even if anti-thyroid drugs (ATD) could be responsible themselves of
adverse-reactions via OS-induced damage (please see Section 4).
5.2.2. Feline Studies
Feline studies evaluating OS in course of thyrotoxicosis are scattered [5,11,24]. In 2009
Viviano et al., [53] quantified erythrocyte reduced glutathione, plasma cysteine, and plasma
ascorbate in clinically ill cats and dogs. Diseases were categorized based on illness severity
assessed at the time of admission (mild, n = 19; moderate, n = 11; and severe, n = 7) and the
“mild category” included two cats (2/37) diagnosed with FHT. Ill cats were characterized
by higher ascorbate concentrations (10.65 µM, range 1.13–25.26) as compared to controls
(3.68 µM, range 0.36–13.57; p = 0.0009), suggesting a possible unique species response to
OS. Branter et al., for instance, assessed antioxidant status in hyperthyroid cats before and
after radioiodine therapy [25]. Fifty-one client-owned hyperthyroid patients that presented
for radioiodine treatment were recruited for the study. Both control and hyperthyroid cats
were screened with a physical exam, cell blood count, biochemical panel, urine specific
gravity (USG), blood pressure and serum total T4. Additional blood was also obtained for
antioxidant assays (including measurement of plasma free vitamin A), along with urine
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for urinary free 8-isoprostane concentrations. Most of the blood screened antioxidants
were not significantly different in hyperthyroid cats compared to controls, but plasma free
vitamin A was higher in diseased animals. Similarly, urinary isoprostanes were increased
in hyperthyroid cats compared to healthy subjects. Both abnormalities normalized after
radioiodine treatment [25]. Candellone et al., [5] screened OS and antioxidant status
markers in cats suffering from thyroidal and non-thyroidal diseases with respect to a
control group of healthy subjects. Forty cats with untreated hyperthyroidism, 45 chronically
ill cats with non-thyroidal illness, and 39 healthy cats were recruited for an observational
cross-sectional study. Determinable reactive oxygen metabolites (d-ROMs) were used as
oxidative stress markers. Antioxidant status was determined using the OXY-Adsorbent
test to quantify the plasma barrier to oxidation. The Oxidative Stress index (OSi) was
calculated as the ratio of d-ROMs and OXY-Adsorbent test values. The OXY-Adsorbent
test results in hyperthyroid cats (265 ± 68µmol HClO/mL) were significantly lower
than those in healthy cats (390± 83µmol HClO/mL; p < 0.01) and chronically ill cats
(306 ± 45µmol HClO/mL, p < 0.05). Moreover, the Osi value in hyperthyroid patients
(0.8± 0.2 CarrU/µmol HClO/mL) was significantly higher (p < 0.001) than that of the
healthy feline (0.3 ± 0.1 CarrU/µmol HClO/mL), [5].
6. Nutritional Management
Nutritional management of FHT could be aimed to pursue three different scopes: a
therapeutic scope, a dietary scope and a synergistic scope.
As already discussed in Section 3.3, the administration of iodine-restricted commercial
diets to hyperthyroid cats (therapeutic scope) is aimed to limit the synthesis of thyroid
hormones, leading to euthyroidism in the majority of cats fed exclusively with this diet [36].
This approach represents the sole treatment option when other solutions (i.e., radio-iodine
therapy, surgery, antithyroid drugs administration) are not feasible. However, the nutri-
tional composition of the commercial iodine-restricted diet is not adequate to completely
satisfy dietary requirements of the hyperthyroid patients as described in Table 3 [15,37,38].
Regardless of the therapeutic approach, a maintenance diet, iodine-unrestricted, but specif-
ically formulated to satisfy nutritional requirements of a geriatric and hyperthyroid patient,
could represent a useful tool to contrast metabolic changes that usually occur in course
of thyrotoxicosis [15]. It should also be considered that dietary management can possibly
exert a synergistic effect with the pharmacological treatment (synergistic scope). In fact,
administration of dietary antioxidants to hyperthyroid patients receiving oral antithyroid
drugs could possibly ameliorate their clinical outcome and reduce MMI-related side-effects,
as already demonstrated in human and animal studies [5,11]. According to the authors, the
pursuit of a dietary and synergistic scope plays a crucial role in the “multimodal approach
to the hyperthyroid cat” that is proposed in the present review. In the following paragraphs,
specific metabolic changes of the hyperthyroid patient will be analyzed, and the dietary
(chapt. 6.1) and synergistic approaches (chapt. 6.2) will be discussed on the basis of the
available literature with regards to in vivo and in vitro models.
Table 3. Nutritional values of three feline commercial diet and comparison with recommendations from [14–16,54,55] and
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6.1. Dietary Scope
Compared to omnivorous species, the cat is an obligatory carnivore. Thus, the pro-
tein requirement must be satisfied in the formulation of a diet for hyperthyroid cats: as
previously described, in these subjects, muscle loss and nitrogen catabolism are a constant
feature and proteins represent the main macronutrient for muscular mass homeostasis.
Based on these considerations, Peterson et al., (2014) recommend that at least 40% of
daily calories should be provided by protein, or greater than or equal to 12 g/100 kcal
of metabolizable energy (ME) [15]. This recommendation remains unchanged once the
euthyroid state is restored. As many cats become sarcopenic with age, feeding older cats
with larger amounts of high-quality protein can slow down muscle mass loss [15,38,54].
Since a fair number of hyperthyroid cats have mild hyperglycemia (subclinical diabetes),
a low carbohydrate dietary regimen is also strongly advised. To this end, a target of less
than 15% of total calories from carbohydrates, or less than 4.5 g/100 kcal ME is indicated.
Indeed, a low carbohydrate diet can prevent the development of overt diabetes after ef-
fective control of hyperthyroidism. The remaining part of the necessary calories must be
guaranteed by lipids. For the underweight hyperthyroid cat, lipid caloric density can be
helpful. However, after euthyroidism has been restored, calorie intake and consequently
body weight and body condition score (BCS) should be routinely checked to maintain ideal
conditions [15]. If hyperthyroid individuals also have CKD, a mild to moderate reduction
in dietary phosphate is warranted, depending on the CKD stage, as assessed according
to International Renal Interest Society (IRIS) guidelines [15,55]. Commercial maintenance
diets contain 125–500 mg/100 kcal of phosphorus; in cats with CKD IRIS stage 1 or 2,
Peterson et al., (2014) suggest a diet containing 125–250 mg of phosphate/100 kcal, which
is necessary to maintain phosphatemia [15]. As described in Table 3, currently few commer-
cial diets present an ideal composition to meet the needs of hyperthyroid cats. Other useful
complementary foods for hyperthyroid patients are potassium gluconate, water-soluble
B-complex vitamins, omega-3 fatty acids, and, as described below, antioxidants.
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6.2. Synergistic Scope
6.2.1. Antioxidant Supplementation
Antioxidant supplementation acts a synergistic scope in course of the pharmacological
treatment. A customized nutrition to the hyperthyroid patient could be formulated not only
to counteract metabolic effects of thyrotoxicosis, but also to improve efficacy and safety of
the pharmacological treatment with antithyroid drugs, as already stated at the beginning of
the present section. In vitro experiments and in vivo studies, performed on experimentally
induced hyperthyroid laboratory animals, already demonstrated that the administration of
antioxidants (mainly curcumin, quercetin, resveratrol and vitamin E) is able to counteract
the OS-related organ damage induced by elevated thyroid hormones [5,7,9,11]. The choice
of the four natural antioxidants mentioned above and contained in widely used fruit
and vegetable products, was driven by two aspects. The first one was the abundancy
of literature showing their efficacy in protecting animal cells and tissues from the OS
injury induced by elevated T4 and/or MMI administration [8,13,56]. The second reason
concerned the mechanism of action and the peculiar clinical effects of each of the selected
compounds [57–61]. For example, curcumin is the most known hepatoprotective agent [58];
resveratrol is capable to improve cardiovascular status [58]; quercetin ameliorates intestinal
absorption and bioavailability of both compounds [59,61], exert a renal protection and
also inhibits thyroid type 1 deiodinase activity [62]; while vitamin E, the antioxidant
par excellence, has a principal function in destroying peroxyl radicals, thus protecting
polyunsaturated fatty acids biological membranes from oxidative damage. The concomitant
supplementation of these compounds, at proper dosages, could possibly ameliorate clinical,
biochemical and pharmacological outcome of hyperthyroid cats treated with MMI, which
are at risk of developing hematological, cardiac, renal and hepatic alterations due to
OS in course of the disease [11]. In the following section, mechanisms of actions and
antioxidant effect of curcumin, quercetin, resveratrol, and vitamin E, administered alone or
in a mixture, in thyroid cell lines or in hyperthyroid rats will be presented. Unfortunately,
specie-specific published studies on feline in vitro-models are unavailable, but the authors
already obtained preliminary data demonstrating the protective effect of quercetin and
curcumin on methimazole and T3 induced oxidative stress in a feline kidney epithelial cell
line (CRFK), (data not shown).
Curcumin
Curcumin is a natural phenolic compound isolated as a yellow pigment from turmeric
(Curcuma longa), used as food coloring (E100) and spice. Furthermore, curcumin finds use
in the Indian and Chinese medicine system. From a biochemical point of view, curcumin
inhibits the inhibitory kappa B alpha kinase (IκBα kinase), a key activator of nuclear factor
κB (NF-κB); such activity makes curcumin effetive in various metabolic endocrine states
such as thyroid disease [58,60]. Additionally, dried turmeric rhizome has no toxicity, as
evidenced by the fact that it has been authorized for human consumption and is widely
used as a food seasoning [58]. The effects of curcumin supplementation on selected aspects
of redox balance of hyperthyroid-induced animal models are summarized in Table 4.
Table 4. Curcumin effects on redox status of hyperthyroid-induced animal models.
Species Organ Investigated Aspect Results Reference
rat cerebral cortex andcerebellum
lipid peroxidation and SOD
activity
↓ to control values of
elevated levels of lipid
peroxidation
↑ activity of SOD and of the
translated products of SOD1
and SOD2
[63]
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Table 4. Cont.
Species Organ Investigated Aspect Results Reference
rat renal cortex
modulation of antioxidant
enzymes (i.e., reduced GSH
and ascorbic acid, SOD, CAT)
and OS parameters (i.e., lipid
peroxidation and protein
carbonylation)
restored control values levels
of OS parameters and small
antioxidant molecules
↑ SOD and CAT
[64]






CAT: catalase; SOD: superoxide dismutase; GSH: glutathione reductase.
Quercetin
Quercetin, a flavonoid contained in many fruits and plants, is used for food purposes
in the formulation of many supplements. Quercetin has beneficial effects in inflammatory
and immune conditions, as well as in thyroid disease. Biochemical variation in laboratory
animals treated with thyroid hormones before and after supplementation with quercetin or
its metabolites are summarized in Table 5.












↓ T3 and T4 levels;






SOD and CAT activity
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no changes in TSH;









rat rutin activity of SLC5A5 andTSHR genes up-regulation [61]
CAT: catalase; SOD: superoxide dismutase; SLC5A5: solute carrier family 5 member 5; TSH: thyroid stimulating hormone; TSHR: thyroid
stimulating hormone receptor; T3: triiodothyronine; T4: thyroxine.
Resveratrol
Resveratrol is a non-flavonoid phenol found in numerous plants such as red grapes
(Vitis vinifera) and the Japanese knotweed (Fallopia japonica). Numerous in vivo and in vitro
studies have documented the antioxidant, anti-inflammatory and anticarcinogenic capabil-
ities of this compound. Moreover, recent experiments highlighted resveratrol anti-thyroid
activity. These results are summarized in Table 6. All these data suggest that activities
of resveratrol may vary in vitro based on the type of cells treated (normal vs cancerous
thyroid cell lines). One possible explanation is the involvement of the aryl hydrocarbon
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receptor (AhR), of which resveratrol is modulator with agonist and antagonist activity in
different cells [68,69]. Previous experiments have shown that AhR activation can cause
alterations in thyroid function, with down-regulation of the expression of the NIS gene.
Another potential mechanism of action behind the anti-thyroidal effect of resveratrol is
the involvement of sirtuins. Resveratrol is an activator of SIRT1, a protein deacetylase that
regulates the expression of several transcription factors and is widely expressed in most
mammalian organs, including the thyroid [68,69].
Table 6. In vivo and in vitro effects of resveratrol treatment.
Model Investigated Aspects Results Reference
in vitro (normal rat
thyroid cells)
NIS gene expression


















and thyroid function Inhibition of both [68]
NIS: sodium/iodide symporter.
Vitamin E
Vitamin E is the best-known antioxidant molecule. Tocotrienols and tocopherols,
in fact, inhibit lipid peroxidation thanks to their capability to eliminate lipid peroxyl
radicals faster than these radicals can react with the side chains of adjacent fatty acids [57].
Furthermore, vitamin E plays a protective role in the membrane by acting as a structural
component. The structural “antioxidant” role of vitamin E may also be partly due to
the downregulation of mitochondrial ROS generation; in fact, it has been demonstrated
that α-tocopherol lowers lipid peroxidation and increases total antioxidant capacity in
liver homogenates and hyperthyroid rat mitochondria [57,65,66]. Results of Vitamin E
supplementation on selected oxidative parameters and antioxidant genes expression in
hyperthyroid-induced animal models are summarized in Table 7.
Table 7. Vitamin E effects on selected parameters of hyperthyroid-induced animal models.
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Table 7. Cont.
Species Organ Investigated Effect Results References
rat liver
hepatic function; hepatic















rat liver antioxidant genes (AOG)expression
alleviated message










AOG: antioxidant genes; CAT: catalase; SOD: superoxide dismutase.
6.2.2. Efficacy of Antioxidant Administration
Human Studies
Human studies demonstrated that antioxidant treatment might be useful in those
hyperthyroid patients with a need for rapid clinical improvement, such as danger of thy-
rotoxic crisis, cardiomyopathy and MMI intolerance [8,10]. Antioxidant supplementation
might be also an indication before a therapeutic dose of radioactive-iodine (I131) admin-
istration or before thyroidectomy. Clearly, antioxidant therapy is not intended to replace
conventional treatment of hyperthyroidism with antithyroid agents such as MMI, but it
could be considered as a new therapeutic tool to improve the clinical manifestation of
this illness, by mean of a multimodal approach. At the best of the author’s knowledge
there are no clinical trials evaluating the efficacy of curcumin, resveratrol and quercetin,
administered as single agents or in a mixture, in the course of human hyperthyroidism.
Most of the studies evaluated the effects of vitamin E on clinical, biochemical and OS
markers, during MMI-treatment or before radio-iodine therapy. In these trials, vitamin
E is usually supplemented in combination with other compounds, which may also exert
antioxidant properties. Of particular interest is a trial from Guerra et al., [8] were an
antioxidant mixture (LAROTABE ®, containing vitamin E 200mg, b-carotene 3 mg, vitamin
C 250 mg, Cu 1 mg, Zn 7.5 mg, Mn 1.5 mg, Se 15 ug) was evaluated in the treatment
of Graves’ disease (GD) in 56 hyperthyroid patients. Patients were divided into three
groups: group A, receiving MMI alone, group B, receiving LAROTABE® alone and group
C receiving both products. Clinical scores, thyroid hormones fluctuations, activities of
antioxidant enzymes and OS markers (plasma MDA) were monitored during an 8 week
period. When hyperthyroid patients were treated with MMI alone (group A), they became
clinically and biochemically euthyroid after approximately 8 weeks. Antioxidant enzymes
normalized their values, and plasma MDA decreased to similar levels of euthyroid controls.
When hyperthyroid patients were treated with antioxidants alone (group B), a significant
decrease of the standardized clinical score was observed after 4 weeks [8]. The activities
of antioxidant enzymes improved, and MDA values returned to normal, even if thyroid
hormones were still above the reference range. The combination of MMI and the antioxi-
dant mixture (group C) shortened the period of normalization of the clinical score, as well
as the normalization of hormonal concentrations from approximately 8 to 4 weeks, when
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compared with the administration of MMI alone. According to these results, treatment of
hyperthyroidism with antioxidants rapidly improved the patients clinically, even in the
presence of high concentrations of thyroid hormones. It also appeared to potentiate the
effects of MMI on the synthesis of thyroid hormones. It could be postulated that elevated
thyroid hormones produce signs and symptoms of hyperthyroidism through an increase
in free radicals as it has been shown in GD [7,43]. When such augmentation is neutralized
with antioxidants, the patients improve clinically, although this treatment has no effect
on the production of thyroid hormones. Authors did not have a clear explanation about
the increased effect of MMI when administered together with the antioxidant mixture.
Antioxidants could interfere with the action of the peroxidase in one or both reactions,
iodide oxidation and/or coupling reaction. As seen in Section 3, in fact, MMI acts by
inhibiting the peroxidase; in this way a synergetic result could be obtained. However, an
inconsistent justification was found for the lack of effect that antioxidant mixture had on
the levels of thyroid hormones when administered without MMI, and it can be speculated
on the possibility of a dose too low to inhibit thyroidal oxidations and hormonal synthesis.
Given the above, antioxidants appear to be an effective coadjutant treatment of hyper-
thyroidism in humans, as they induce a rapid clinical improvement, evident as soon as 4
weeks after their administration [8].
Feline Studies
Up to date, there is only one study from Candellone et al. [11] evaluating the effect of
dietary antioxidants supplementation (curcumin, resveratrol, quercetin and vitamin E) in
MMI-treated hyperthyroid cats. A series of hyperthyroid client-owned feline patients were
randomly allocated in group M + A (MMI + antioxidants) or group M (MMI + placebo).
Clinical findings, haemato-biochemical parameters, concentration of circulating thyroid
hormones, selected markers of OS and antioxidant status [i.e., determinable reactive oxygen
metabolites (dROMs), OXY-adsorbent test values, and oxidative stress index (OSi) values],
and MMI-related adverse events were monitored. Group M had a significantly increase
in dROMs and OSi values during the study. Likewise, OXY-absorbent test values were
significantly higher in group M + A than in group M at the end of the trial. Moreover, the
occurrence rate of MMI-adverse events in the group treated with antioxidants was lower
than in the untreated cohort of cats. These preliminary results show that the dietary sup-
plementation of antioxidants in hyperthyroid feline patients receiving ATD could exerts a
protective effect against OS, likely contributing to the reduction of drug idiosyncrasies [11].
7. Conclusions
Hyperthyroidism in accompanied, both in humans and in animal models, by increased
free radical formation. Anti-thyroid drugs, such as MMI, are able to restore euthyroidism in
diseased feline patients, but they could be responsible for adverse reactions leading to organ
damage and to a further increase in redox imbalance. Dietary antioxidant supplementation
of molecules such vitamin E, curcumin, resveratrol and quercetin showed a protective
effect, in vitro and in vivo trials, on MMI-induced tissue injury and on the amelioration of
clinical signs related to thyrotoxicity. Correcting the state of impaired redox balance with a
customized nutritional regimen in addition to traditional thyrostatic therapy could be then
advised also while managing feline hyperthyroidism.
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Abbreviations
ATD: anti-thyroid drugs; CAT: catalase; CKD: chronic kidney disease;CMZ: carbimazole; CYP 450:
cytochrome P450; DMB: dry matter basis; d-ROMs: determinable reactive oxygen species; DUOX:
double oxidase; FHT: feline hyperthyroidism; GD: Basedow-Graves’ disease; GFR: glomerular filtra-
tion rate; GO: Graves’ orbitopathy; GPx: glutathione peroxidase; GSH: reduced glutathione; MDA:
malondialdehyde; ME: metabolizable energy; MMI: methimazole; OS: oxidative stress; Osi: oxidative
stress index; SDMA: symmetric dimethylarginine; SOD: superoxide dismutase; T3: tri-iodothyronine;
T4: tetra-iodothyronine or thyroxine; TBARS: thiobarbituric acid reactive substances; TPO: thyroid
peroxidase; TSH: thyroid stimulating hormone.
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